IP Library Granted Patent US 9,266,929
Granted Patent B2
US 9,266,929 · App. 14/450,075 · Granted Feb 23, 2016

Patent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,266,929
App. No.
14/450,075
Granted
Feb 23, 2016
Kind
B2
Abstract

The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

Claims (17)

1. A method of preparing an immunogenic composition comprising:

(a) expressing in E. coli a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO: 2536, wherein the fragment comprises 16 or more consecutive amino acids from the amino acid sequence, wherein the polypeptide is immunogenic;

(b) purifying the polypeptide;

(c) preparing the immunogenic composition by combining the purified polypeptide with an aluminum salt adjuvant.

2. The method of claim 1 , wherein the fragment comprises 20 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 2536.

3. The method of claim 1 , wherein the immunogenic composition further comprises a pharmaceutically acceptable carrier.

4. The method of claim 1 , wherein the aluminum salt is aluminum phosphate.

5. The method of claim 3 , wherein the aluminum salt is aluminum phosphate.

6. The method of claim 1 , wherein the immunogenic composition further comprises a pH buffering agent.

7. The method of claim 6 , wherein the immunogenic composition further comprises a pH buffering agent.

8. A method of preparing an immunogenic composition comprising combining a purified polypeptide with an aluminum salt adjuvant, wherein the purified polypeptide was expressed in, and purified from, E. coli ; comprises a fragment of the amino acid sequence of SEQ ID NO: 2536, wherein the fragment comprises 16 or more consecutive amino acids from the amino acid sequence; and is immunogenic.

9. The method of claim 8 , wherein the fragment comprises 20 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 2536.

10. The method of claim 8 , wherein the immunogenic composition further comprises a pharmaceutically acceptable carrier.

11. The method of claim 8 , wherein the aluminum salt is aluminum phosphate.

12. The method of claim 10 , wherein the aluminum salt is aluminum phosphate.

13. The method of claim 8 , wherein the immunogenic composition further comprises a pH buffering agent.

14. The method of claim 12 , wherein the immunogenic composition further comprises a pH buffering agent.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2015
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 035231/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2015
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 035219/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2015
From: J. CRAIG VENTER INSTITUTE, INC.
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 035155/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2015
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS AG
Reel/Frame 035155/0910 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: FRASER, CLAIRE; HICKEY, ERIN; PETERSEN, JEREMY; TETTELIN, HERVE; VENTER, J. CRAIG
To: J. CRAIG VENTER INSTITUTE, INC.
Reel/Frame 035097/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: GALEOTTI, CESIRA; GRANDI, GUIDO; MASIGNANI, VEGA; MORA, MARIROSA; PIZZA, MARIAGRAZIA; RAPPUOLI, RINO; RATTI, GIULIO; SCARLATO, VINCENZO; SCARSELLI, MARIA
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 035097/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 035097/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS AG
Reel/Frame 035097/0909 →